Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting for PMX PMA
🤖 D.R.A.F.T. Summary
• Company gains further clarity on the additional information required to advance its PMA review • FDA did not request an additional clinical trial following its 100-day review of the PMA application • Company does not currently expect a material change to its overall regulatory timeline TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) — Spectral Medical […]
Outlets covering this story
Financial Post
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →